

Thomas Cunningham, PhD
Director, Finance & Operations
Helen Diller Family
Comprehensive Cancer Center

185 Berry Street Ste 6600
UCSF Box 0981
San Francisco, CA 94143
415.353-7278 (voice)
cunninghamt@cc.ucsf.edu

Dear Sponsor:

Thank you for choosing Helen Diller Comprehensive Cancer Center at UCSF for your research project. I am enclosing our standard non-refundable fee schedule for all clinical trials that are done through our Investigational Trials Resource (ITR). These fees are retained by our institution for essential costs and are not included in the investigator compensation. Whether or not a study is officially initiated, the non-refundable fees are still payable even if a contract is never fully executed. These fees represent the fair market value of any normal start up activities actually performed in our region and are non-negotiable.

Non-refundable fees, inclusive of overhead at 33%:

Regulatory Documentation Preparation Fee	\$1,596
Coverage Analysis Fee	\$3,724
Institutional Review Board/Committee for Human Research Review Fee (IRB/CHR)	\$3,591
Scientific Review Committee (PRC) Fee	\$1,995
Electronic Regulatory Document Platform Usage Fee	\$3,325
Pharmacy Setup Fee	\$3,990
Total	\$18,221

The following fees, inclusive of overhead at 33%, are also non-negotiable and will be invoiced only if the event occurs:

Pharmacy Annual Maintenance	\$1,995
Pharmacy Close-Out	\$665
Investigational Pharmacy Drug Service Fee	\$200
Coverage Analysis Fee for protocol amendments	\$1,330
Cancer Center Annual Maintenance Fee	\$2,660
IRB Annual Review (Full Committee Review)	\$1,600
Serious Adverse Event Fee	\$465
Study Close-Out Fee	\$2,660

In the event of a Sponsor/FDA Audit or Inspection (i.e., not "for cause") conducted at Study Center in connection with the Sponsor's regulatory filing, the Sponsor will reimburse the Study Center for its costs to facilitate the audit. The audit fees will be mutually agreed to by the Sponsor and UCSF, if an audit should occur.

Please let us know if you have any further questions.

Regards,



Thomas Cunningham, Ph.D.
Director of Finance and Operations
UCSF Helen Diller Family Comprehensive Cancer Center